Pharmacogenomics in neuro-oncology;Farmacogenómica en neurooncología

Revista de Neurologia

Volumn 43, Issue 6, 2006, Pages 353-356

  Riese, Hans H ^a,b   Baez J M ^a  

^a Departamento de Desarrollo de Negocio   (Spain)

^b Neuropharma SA   (Spain)

Author keywords

Brain tumour; Genomic; Personalized medicine; Pharmacogenomics; Proteomic

Indexed keywords

6 O METHYLGUANINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIPODOPHYLLOTOXIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; TENIPOSIDE; VINCRISTINE;

BRAIN TUMOR; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GLIOMA; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL TECHNOLOGY; MICROARRAY ANALYSIS; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PREDICTION; PROTEIN ANALYSIS; PROTEOMICS; RECEPTOR GENE; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT; DNA MICROARRAY; INSTRUMENTATION; MASS SPECTROMETRY; METHODOLOGY; NEUROLOGY; ONCOLOGY; PHARMACOGENETICS;

BRAIN NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; NEUROLOGY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 35348834907     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4306.2005496     Document Type: Review

References (10)

1. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predicitive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-501.
2. Duffaud F, Blay JY. Gastrointestinal stromal tumors: biology and treatment. Oncology 2003; 65: 187-97.
3. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-88.
4. Grem JL. Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer. Semin Oncol 2005; 32: 120-7.
5. Nakajima M, Yokoi T. Cancer pharmacogenomics: achievements in basic research. Int J Clin Oncol 2005; 10: 14-9.
6. Balaña C, Ramírez JL, Tarón M, Roussos Y, Ariza A, Ballester R, et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003; 9: 1461-8.
7. Esteller M, García-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-4.
8. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10: 1871-4.
9. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollán M, Aguirre-Cruz L, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10: 4933-8.
10. Zheng PP, Luider TM, Pieters R, Avezaat CJ, Van den Bent MJ, Sillevis-Smitt PA, et al. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 2003; 62: 855-62.